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Abstract
Background: Pre-marketing clinical studies of tegaserod suggested an increased risk of abdominal surgery,
particularly cholecystectomy. We sought to quantify the association between tegaserod use and the occurrence of
abdominal or pelvic surgery, including cholecystectomy.
Methods: This cohort study was conducted within an insured population. Tegaserod initiators and similar persons
who did not initiate tegaserod were followed for up to six months for the occurrence of abdominal or pelvic
surgery. Surgical procedures were identified from health insurance claims validated by review of medical records.
The incidence of confirmed outcomes was compared using both as-matched and as-treated analyses.
Results: Among 2,762 tegaserod initiators, there were 94 abdominal or pelvic surgeries (36 gallbladder): among
2,762 comparators there were 134 abdominal or pelvic surgeries (37 gallbladder) (hazard ratio HR]= 0.70, 95%
confidence interval [C.I.] = 0.54-0.91 overall, HR = 0.98, 95% C.I. = 0.62-1.55 for gallbladder). Current tegaserod
exposure compared to nonexposure was associated with a rate ratio [RR] of 0.68 (95% C.I. = 0.48-0.95) overall, while
the RR was 0.99 (95% C.I. = 0.56-1.77) for gallbladder surgery.
Conclusions: In this study, tegaserod use was not found to increase the risk of abdominal or pelvic surgery nor the
specific subset of gallbladder surgery.
Keywords: Abdominal surgery, Tegaserod, Cohort study
Background
Tegaserod (Zelnorm
W/Zelmac
W) is a selective, partial
serotonin type 4 (5HT4) receptor agonist that has thera-
peutic benefit in patients with irritable bowel syndrome
with constipation (IBS-C) and chronic idiopathic consti-
pation [1-4]. It was approved for clinical use in the U.S.
and 61 other countries. A review of the pre-marketing
studies of tegaserod for treatment of IBS-C indicated an
imbalance in the number of abdominal surgeries
observed among the tegaserod treated patients (9/2,965;
0.3%) relative to patients receiving placebo (3/1,740;
0.2%), and an imbalance in cholecystectomy among
tegaserod recipients (5 of 2,965; 0.17%) relative to pla-
cebo (1 of 1,740; 0.06%) [5]. Although abdominal surgery
and cholecystectomy occurred, respectively, 1.7 and 3
times as often in the tegaserod-treated group, the rarity
of these procedures during the clinical trials meant that
the apparent difference between treatment groups could
reasonably be attributed to chance. Furthermore, clinical
review of the medical records for these cases suggested
alternative etiologies for some of the procedures suggest-
ing that the difference in incidence between tegaserod
and placebo groups was even smaller than the total
numbers indicated [6].
Our aim was to quantify the association between tega-
serod exposure and the occurrence of abdominal or pel-
vic surgery including gallbladder surgery. We conducted
the Zelnorm Epidemiologic Study (ZEST) as a post-
marketing study within a health insurance database that
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tice for patients across the United States [7].
Since this study was completed, results of pooled
safety analyses of 29 placebo-controlled clinical studies
(11,614 patients treated with tegaserod and 7,031 treated
with placebo), revealed a small yet statistically significant
(13 tegaserod vs. 1 placebo, p =0.024) imbalance in the
number of patients having a cardiovascular ischemic
event (myocardial infarction, stroke, unstable angina,
etc.). Following a review of these data with health au-
thorities, the marketing and sales of Zelnorm
W/Zelmac
W
were suspended in the U.S.A, and at least twenty other
countries. Subsequent to this action, the epidemiological
data from patients taking tegaserod and comparator
groups were evaluated for evidence of adverse cardiovas-
cular ischemic events, and no increased risk was found
for tegaserod [8,9]. Tegaserod does remain available in
the US and four other countries under a special compas-
sionate use program and is also still marketed in 5 other
countries. In addition, other drugs with 5HT4 agonist ac-
tivity are under clinical trial evaluation or submitted for
regulatory approval. Accordingly, the results of this
study remain pertinent to patient care.
Methods
This cohort study was conducted within the Ingenix
Research Database, which includes persons with both
commercial (employed people and their dependents)
and Medicare supplement health insurance and is geo-
graphically dispersed across the US. The database
includes information on enrollee age, sex, enrolled
dates and claims for reimbursement for all types of
health care services. Each reimbursement claim is
linked to an encrypted enrollee identifier and contains
patient diagnoses, coded according to the International
Classification of Diseases, Ninth Revision (ICD-9), with
medical procedures coded using one of the following:
ICD-9 procedure codes, Current Procedural Termin-
ology codes, or Health Care Financing Agency Com-
mon Procedure Coding System level II codes.
Pharmacy claims for dispensing of prescription drugs
are also included in the database, with the drug name
in addition to formulation and number of days sup-
plied. The data are audited, and the validity of the
claims has been previously documented [10].
The cohorts consisted of tegaserod initiators and com-
parators who were contemporary non-initiators of tega-
serod. Patients were counted as tegaserod initiators if a
first known dispensing was preceded by at least six
months in the database, and comparators similarly
needed at least six months of preceding database enroll-
ment for eligibility. The comparators were chosen to
have similar characteristics to the tegaserod initiators
with respect to numerous baseline characteristics and
claims for medical services beyond calendar time. This
study was conducted across the first year of tegaserod
availability in the US, and included initiators in each cal-
endar quarter (4th quarter 2002, 1st quarter 2003, 2nd
quarter 2003, or 3rd quarter 2003) who were selected,
along with a pool of patients who did not initiate tega-
serod within the same calendar quarter.
We identified tegaserod initiators and a pool of poten-
tial comparators who were selected on the basis of a
diagnosis code for functional digestive disease (ICD-9:
564.x), or other abdomen or pelvis symptoms (ICD-9:
789.x), or gastrointestinal system symptoms (ICD-9: 787.
x) contemporaneous with the tegaserod initiators. We
characterized patients with respect to a wide range of
medical and pharmacy insurance claims (including
demographics, healthcare utilization, calendar time,
gastrointestinal care correlates, surgical procedures, and
empirically-identified variables) during the 6-months
preceding the initial tegaserod dispensing (or, for the
non-initiators, a date that was assigned at random from
among the tegaserod initiation dates), and a multivari-
able balancing technique (propensity score matching)
was used to produce similar groups [11,12]. The cohorts
were formed on a quarterly basis and pooled for the out-
come analysis [13]. The propensity score modeling and
the matching based on it was conducted separately each
calendar quarter, so that each quarter’s model could vary
both with respect to the variables included and the
weight of each variable, accounting for changes in the
way tegaserod was prescribed over the time of the study.
A comparator patient was selected for each of the tega-
serod initiators on the basis of a narrow and fixed caliper
of propensity score (0.01).
Tegaserod initiators and comparators were followed
for up to 183 days from the date of cohort entry (less
if members disenrolled prior to the end of the
183 days) for the occurrence of abdominal surgery.
We identified potential surgeries through insurance
claims and sought medical records relating to the sur-
geries identified in order to confirm that the proced-
ure met the study definition of surgery. Blinded
medical records were all reviewed by an independent
clinical expert panel composed of four physicians with
a range of clinical expertise who arrived at a consen-
sus about whether each potential case met the study
definition of abdominal or pelvic surgery, the type of
surgery and its date. (Appendix A) Study outcomes
included in this report and analyses involving them
are based only on outcomes that were confirmed
through this process.
Counts of abdominal or pelvic surgery and gallbladder
surgery among tegaserod initiators and comparators
were summarized along with measures of comparison
between the cohorts and associated confidence intervals.
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baseline demographics, health conditions and health ser-
vice utilization, and provide both “as-matched” analyses
that correspond to intent-to-treat analyses, and “as-
treated” analyses that update tegaserod exposure accord-
ing to pharmacy claims that indicated dispensing of
tegaserod during follow-up.
The incidence of abdominal or pelvic surgeries during
the follow-up of the tegaserod initiator or comparator
cohorts was analyzed using proportional hazards regres-
sion, with separate models developed for abdominal and
pelvic surgeries and for gallbladder surgeries. We also
incorporated covariate adjustment (even though the pro-
pensity score matching process largely removed differ-
ences between the groups). This adjustment served both
to address the small remaining differences between tega-
serod users and comparators with respect to these vari-
ables, and to show the association between these
variables and the risk of abdominal and pelvic surgeries
or gallbladder surgeries. Covariates used for this adjust-
ment were selected in a stepwise process in separate
models to evaluate prediction of abdominal or pelvic
surgery or gallbladder surgery.
To account for this change in exposure during follow-
up, we conducted an analysis that combined person-
time into similar categories of tegaserod exposure
(current, recent, past, or non-user). The “current tega-
serod” category started the day after a dispensing of
tegaserod and continued through the end of the number
of days supplied by that dispensing plus 14 days. The
“recent tegaserod” category started at the end of the
“current tegaserod” category and continued for up to
28 days, and the “past tegaserod use” category charac-
terizes all of the time thereafter. The “non-user” category
was for persons who had no prior or current use of tega-
serod within the study time frame. Each new dispensing
of tegaserod reset the use category to “current tega-
serod” and the other categories followed. All surgeries
representing study outcomes that occurred during the
follow-up period were assigned to one of the four
tegaserod-use categories depending on the exposure sta-
tus of the person at the time of the event.
A Poisson regression model was used to compare the
incidence rate of surgery across tegaserod exposure
categories incorporating covariate adjustment, since
changes in therapy may be related to patient characteris-
tics, so that exposure categories may not be as well
balanced with respect to covariates as were the
originally-matched cohorts. Covariates for this analysis
arose from those selected for adjustment in the “as
balanced” analysis.
Analyses were conducted using SAS (version 8). The
study protocol was approved by the New England Insti-
tutional Review Board.
Results and discussion
There were 2,853 eligible tegaserod initiators across the
four study accrual periods, of which 2,762 (96.8%) were
matched to 2,762 comparators. The variables included in
the propensity score varied according to the matching
block, and included an average of 77 (range 52–107)
variables. The resulting score was highly discriminating
between tegaserod initiators and non-initiators (average
c-statistic =0.90). Characteristics of the tegaserod initia-
tors and their matched comparators did not differ sub-
stantially for any of the characteristics that were part of
the propensity score (demographics, pre-existing diagno-
ses or medical conditions, procedures, prior drug use,
and baseline healthcare utilization). (Table 1) We did
not exclude people with claims indicating abdominal
surgery in the six-month baseline period (preceding co-
hort entry), and the occurrence of claims for abdominal
surgery during baseline did not differ substantially be-
tween the cohorts (17.2% vs 15.2% for any abdominal
surgery and 1.7% vs 1.5% for gallbladder surgery).
We identified 456 potential abdominal or pelvic sur-
geries on the basis of claims data during the 6-month
follow-up of the matched cohorts and sought the med-
ical records for 448 (98.2%) of them, excluding only
those that could be ruled out on the basis of a claims re-
view alone. We obtained 376 of the 448 (83.9%)
requested medical records, and the remainder could not
be obtained. The expert clinical review panel confirmed
that 228 of the 376 (60.6%) potential abdominal or pelvic
surgeries identified met the study outcome definition
(for the subset of gallbladder surgeries, 73 of the 92
(79.3%) met the study outcome definition). The surgeries
not meeting the study definition tended to be ones per-
formed under local anesthesia or non-surgical abdominal
or pelvic procedures. Only confirmed surgeries meeting
study definition were included in outcome analyses.
The “as matched” analysis was conducted separately for
all abdominal surgeries combined (Table 2 and Figure 1)
and for gallbladder surgeries (Table 3 and Figure 2). The
incidence of all surgeries combined was lower in the tega-
serod initiating cohort than it was in the comparator co-
hort (HR=0.70, 95% C.I. = 0.54-0.91). Adjusting for
baseline risk factors did not substantially alter this associ-
ation (adjusted HR=0.71, 95% C.I. = 0.55-0.93). The inci-
dence of gallbladder surgeries was almost identical in the
two cohorts (HR=0.98, 95% C.I. = 0.62-1.55), and this
was also unaffected by adjustment for baseline risk factors
(adjusted HR=0.99, 95% C.I. = 0.62-1.58).
The effect of tegaserod on the incidence of abdominal or
pelvic surgery was not different among the subset of the
cohorts who were female (HR= 0.70, 95% C.I. = 0.53-0.92),
or who had a baseline claim for constipation (HR=0.62,
95% C.I. = 0.45-0.86), or who had a baseline claim for IBS
(HR= 0.74, 95% C.I= 0.53-1.03) suggesting no effect
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association between tegaserod and gallbladder surgery was
also consistent across strata (HR=1.02, 95% C.I. = 0.63-
1.65 for women; HR= 0.98 95% C.I. = 0.58-1.65 for those
with a baseline claim for constipation; HR=1.04, 95% C.I.
= 0.57-1.90 for those with a baseline claim for IBS). When
we restricted the analysis of gallbladder surgeries to chole-
cystectomy, we found almost identical results (only 1 case
of gallbladder surgery was not a cholecystectomy).
The “as-treated” analysis was also conducted separ-
ately for all abdominal surgeries (Table 4) combined and
for gallbladder surgeries (Table 5). The incidence of all
abdominal surgeries combined was similar in each of the
different exposure categories in relation to tegaserod dis-
pensing (current, recent, past, and non-use). The inci-
dence rate of all abdominal surgeries, was not increased
among either current tegaserod use (0.08 surgeries/
person-year, RR =0.68, 95% C.I. = 0.48-0.95) or past
tegaserod use (0.07 surgeries/person-year, RR =0.59,
95% C.I. 0.39-0.89) compared to non-use (0.12 surgeries/
person-year, RR = 1.00, reference category). To the con-
trary, the incidence was statistically lower during these
Table 1 Characteristics of tegaserod initiators and comparators at baseline
1
Characteristic or Condition Tegaserod initiators (N=2,762) Comparison cohort (N=2,762)
N%N%
Age group
0-29 386 14.0% 386 14.0%
30-49 1,416 51.3% 1,412 51.1%
50+ 960 34.8% 964 34.9%
Sex
Female 2,496 90.4% 2,435 88.2%
Region
Northeast 73 2.6% 70 2.5%
South & Southeast 1,256 45.5% 1,312 47.5%
Midwest 1,228 44.5% 1,159 42.0%
West 205 7.4% 221 8.0%
Select Baseline Diagnoses
Abdomen / Pelvis Symptoms (ICD-9 789) 1,413 51.2% 1,417 51.3%
Irritable Bowel Syndrome (ICD-9 564.1) 1,150 41.6% 1,117 40.4%
Constipation (ICD-9 564.0) 1,027 37.2% 967 35.0%
GI System Symptoms (ICD-9 787) 886 32.1% 1,050 38.0%
Select Baseline Procedures
Surgical Pathology (CPT 88305) 696 25.2% 700 25.3%
Colon Procedures (CPT 643 23.3% 665 24.1%
CT Scan Abdomen (CPT 74150–74175) 413 15.0% 426 15.4%
Abdominal Ultrasound (CPT 381 13.8% 401 14.5%
Gallbladder Radiography (CPT 84 3.0% 66 2.4%
Gallbladder Surgery (CPT 46 1.7% 42 1.5%
Baseline Drug Classes Dispensed
Proton Pump Inhibitors 1,029 37.3% 1,059 38.3%
Analgesics, Narcotics 955 34.6% 998 36.1%
Serotonin Specific Reuptake Inhibitor 692 25.1% 686 24.8%
Laxative Drugs 533 19.3% 522 18.9%
Baseline Healthcare Utilization Mean Median Mean Median
Total Cost ($) 4,319.40 2,127.77 4,750.59 2,254.55
Physician Costs (US$) 1,501.48 828.12 1,576.03 849.34
Cost of Pharmaceuticals (US$) 923.33 461.04 937.55 405.71
Gastroenterologist Visits 1.6 1 1.6 0
Number of Drug Classes Dispensed 7.9 7 7.8 7
1 Defined as the six-month period preceding start of follow-up.
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category, but not for the tegaserod recent-use exposure
category (0.14 surgeries/person-year, RR =1.17, 95% C.I.
0.76-1.80). For gallbladder surgery the rate of surgery
per person year for the current-use group (0.03
surgeries/person-year, RR =0.99, 95% C.I. = 0.56-1.77)
and past-use group (0.02 surgeries/person-year, RR =
0.85, 95% C.I. = 0.42-1.72) was similar to the non-use
group (0.03 surgeries/person-year, RR =1.00, reference
category) while the recent-use group was less similar,
Table 2 Incidence of abdominal or pelvic surgeries among tegaserod initiators and comparators (as-matched analysis)
Variable Events Person
years
I.R.
1 95% C.I. Hazard
ratio
2
95% C.I. Hazard
ratio
3
95% C.I.
Low High Low High Low High
Exposure
Tegaserod Initiators 94 1,101 0.09 0.07 0.10 0.70 0.54 0.91 0.71 0.55 0.93
Comparators 134 1,100 0.12 0.10 0.14 1.00 1.00
Gender
Female 207 1,963 0.11 0.09 0.12 1.00 1.00
Male 21 237 0.09 0.05 0.14 0.83 0.53 1.31 0.74 0.47 1.18
Age
0 – 29 25 295 0.08 0.06 0.12 0.65 0.45 0.96 0.63 0.41 0.94
30 – 49 146 1118 0.13 0.11 0.15 1.00 1.00
50 + 57 788 0.07 0.06 0.09 0.55 0.26 0.94 0.65 0.30 1.02
Abdominal Surgery Risk Factors
Cholelithiasis 19 43 0.45 0.27 0.69 5.06 2.85 8.96
Inguinal Hernia 3 7 0.43 0.09 1.27 3.82 1.17 12.49
Diagnostic Procedures, Abdomen/Pelvis 3 5 0.61 0.13 1.79 4.34 1.32 14.22
Radiologic Small Bowel Exam 21 59 0.35 0.22 0.54 2.35 1.43 3.86
Urinary Tract Diagnostic Procedures 15 71 0.21 0.12 0.35 2.11 1.14 3.90
Gallbladder Radiography 19 50 0.38 0.23 0.60 2.82 1.69 4.69
1 Incidence rate (IR), events per person year.
2 Adjusted for age, gender, region, calendar year and quarter of cohort entry.
3 Adjusted for. age, gender, region, antidepressants, appendicitis, gallbladder surgeries, cholelithiasis, colonoscopy, irritable bowel syndrome, gastritis/duodenitis,
hepatitis, disorders of liver, inguinal hernia, male genital surgery, MRI abdomen, diagnostic procedures, abdomen/pelvis, small bowel radiology, rectum/anus
diagnostic procedures, urinary tract diagnostic procedures, urinary tract surgeries, gallbladder radiography, abdominal radiology, calendar year and quarter of
cohort entry.
Figure 1 Time to First Abdominal or Pelvic Surgery (As-Matched Analysis).
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son-year, RR = 1.78, 95% C.I. 0.88-3.59).
In these data, which reflect tegaserod use in actual clin-
ical practice, we found no evidence for an increased risk
of abdominal or pelvic surgery, or specifically gallbladder
surgery, among persons who used the 5HT4 selective re-
ceptor partial agonist, tegaserod. This finding was consist-
ently observed under different definitions of exposure to
Table 3 Incidence of gallbladder surgery among tegaserod initiators and comparators (as-matched analysis)
Variable Events Person
years
I.R.
1 95% Confidence
interval
Hazard
ratio
2
95% Confidence
interval
Hazard
ratio
3
95% Confidence
interval
Low High Low High Low High
Exposure
Tegaserod Initiators 36 1,115 0.03 0.02 0.04 0.98 0.62 1.55 0.99 0.62 1.58
Comparators 37 1,125 0.03 0.02 0.05 1.00 1.00
Gender
Female 67 1,999 0.03 0.03 0.04 1.00 1.00
Male 6 242 0.02 0.01 0.05 0.76 0.33 1.75 0.50 0.20 1.24
Age
0 – 29 9 299 0.03 0.01 0.06 0.77 0.56 1.21 0.77 0.56 1.22
30 – 49 45 1144 0.04 0.03 0.05 1.00 1.00
50 + 19 797 0.02 0.01 0.04 0.61 0.55 0.81 0.61 0.52 0.83
Gallbladder Surgery Risk Factors
Other Diseases of Appendix 1 2 0.49 0.01 2.71 13.60 1.77 401.41
Gallbladder or Bile Duct Surgeries 3 30 0.10 0.02 0.29 0.07 0.02 0.31
Acute Cholecystitis (575.0) 4 8 0.47 0.13 1.21 5.34 1.42 20.06
Cholelithiasis (574) 14 44 0.32 0.18 0.54 8.59 4.09 18.01
Constipation (564.0) 17 814 0.02 0.01 0.03 0.58 0.33 1.00
Abdominal Ultrasound 33 283 0.12 0.08 0.02 2.84 1.62 4.98
Radiographic Visualization, Gallbladder 13 51 0.25 0.13 0.43 3.31 1.63 6.71
1 Incidence rate (IR) per person year.
2 Adjusted for age, gender, region, and calendar year and quarter of cohort entry.
3 Adjusted for age, gender, region, and calendar year and quarter of cohort entry, number of abdominal pain physician visits, appendicitis, gallbladder surgery,
cholecystitis, cholelithiasis, constipation, disorders of stomach and duodenum, liver surgery, peptic ulcer disease, sucralfate, abdominal ultrasound, and
radiographic visualization of the gallbladder.
Figure 2 Time to First Gallbladder Surgery (As-Matched Analysis).
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Variable Events Person
years
I.R.
1 95% Confidence interval Rate
ratio
1
95% Confidence Interval
Low High Low High
Tegaserod Use
Current 43 542 0.08 0.06 0.11 0.68 0.48 0.95
Recent 25 177 0.14 0.09 0.21 1.17 0.76 1.80
Past 28 393 0.07 0.05 0.10 0.59 0.39 0.89
Non-Use 132 1,090 0.12 0.10 0.14 1.00
Gender
Female 207 1,963 0.11 0.09 0.12 1.00
Male 21 237 0.09 0.05 0.14 0.85 0.54 1.33
Age
0 - 29 25 289 0.09 0.06 0.13 1.00
30 - 49 144 1,110 0.13 0.11 0.15 1.47 0.96 2.26
50 + 59 802 0.07 0.06 0.09 0.85 0.53 1.36
Surgery Risk Factors
Cholelithiasis (574) 19 43 0.45 0.27 0.69 3.25 2.00 5.28
Colonoscopy (45355–45387) 54 496 0.11 0.08 0.14 0.95 0.69 1.31
Irritable Bowel Syndrome (564.1) 89 910 0.10 0.08 0.12 0.88 0.67 1.15
Gastritis and Duodenitis (535) 47 312 0.15 0.11 0.20 1.37 0.98 1.91
Diagnostic Procedures
2 80 437 0.18 0.15 0.23 1.92 1.45 2.55
1 Adjusted for gender, age, cholelithiasis, colonoscopy, irritable bowel syndrome, gastritis and duodenitis, and diagnostic procedures.
2 Composite variable consisting of MRI abdomen, other diagnostic procedures involving the abdomen or pelvis, radiologic small bowel examination, rectum or
anus diagnostic procedures, urinary tract diagnostic procedures, radiographic visualization of the gallbladder, and abdominal radiologic examination.
Table 5 Incidence rates and relative risks of gallbladder surgery (as-treated analysis)
Variable Events Person
years
Incidence
rate
1
95% Confidence interval Rate
ratio
1
95% Confidence interval
Low High Low High
Tegaserod Use
Current 17 545 0.03 0.02 0.05 0.99 0.56 1.77
Recent 10 179 0.06 0.03 0.10 1.78 0.88 3.59
Past 10 401 0.02 0.01 0.05 0.85 0.42 1.72
Non-Use 36 1,115 0.03 0.02 0.04 1.00
Gender
Female 67 1,999 0.03 0.03 0.04 1.00
Male 6 242 0.02 0.01 0.05 0.68 0.29 1.57
Age
0 - 29 9 293 0.03 0.01 0.06 1.00
30 - 49 44 1,135 0.04 0.03 0.05 1.35 0.66 2.77
50 + 20 813 0.02 0.02 0.04 0.87 0.39 1.91
Gallbladder Surgery Risk Factors
Cholelithiasis (574) 14 44 0.32 0.18 0.54 8.51 4.23 17.14
Gallbladder or Bile Duct Surgeries 3 30 0.10 0.02 0.29 0.20 0.06 0.73
Constipation (564.0) 17 814 0.02 0.01 0.03 0.56 0.32 0.96
Diagnostic Procedures
2 35 295 0.12 0.08 0.17 4.44 2.67 7.39
1 Adjusted for gender, age, cholelithiasis, gallbladder surgery, constipation, and diagnostic procedures.
2 Composite variable consisting of abdominal ultrasound and radiographic visualization of the gallbladder.
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line imbalances between tegaserod initiators and their
comparators. These results come from almost complete
sampling of tegaserod initiators within a defined popula-
tion with health insurance and represent usual patient
care across a wide geographic area in the US; thus, we be-
lieve the results can be broadly generalized to tegaserod
users. The explanation for the apparent elevation in risk
of abdominal surgery during periods of recent tegaserod
use is not apparent in the data available for this study.
However, it may be related to clinical use of tegaserod for
a short period if IBS is part of the initial differential diag-
nosis for a patient, and the drug is discontinued as the
diagnostic picture evolves (perhaps with the introduction
of evidence to support another diagnosis for which sur-
gery is indicated) or a rebound of symptoms with discon-
tinuation of tegaserod.
The Phase III clinical trial experience with tegaserod
had suggested an incidence of abdominal surgeries of
about one percent during approximately one-month of
follow-up time, with gallbladder surgeries being a subset
of that [1-4]. The higher absolute incidence of surgery
that we observed in ZEST (4.1% for abdominal and pelvic
surgeries and 1.3% for gallbladder surgeries) with a
6 month follow-up, likely reflects both the longer average
follow-up time and differences between a clinical trial
setting involving highly selected patients who meet study
inclusion and exclusion criteria, and real-world clinical
practice where tegaserod is prescribed to a broader mix
of patients. The select subset of candidates for tegaserod
therapy who qualify for clinical trials may be at a lower
short-term risk of surgery than the patients who actually
receive tegaserod in clinical practice. Even with the
higher absolute incidence rate of surgeries observed in
this study of tegaserod use in the “real-world”,w e
observed no increased risk for abdominal or pelvic sur-
gery or for cholecystectomy among patients treated with
tegaserod compared to matched non-tegaserod users.
Another study within this same insurance database
found an incidence rate of 119/10,000 person-years for
gallbladder surgery and 936/10,000 person-years for ab-
dominal and pelvic surgery among persons with all
forms of IBS [14]. Corresponding rates of 37/10,000
person-years for gallbladder surgery and 488/10,000
person-years for abdominal and pelvic surgery among
similar persons selected from the health insurance popu-
lation, but without a specific diagnosis of IBS, indicate
that having IBS increases the risk of both of these sur-
gery categories. An increased risk of abdominal and pel-
vic surgery, and specifically of cholecystectomy in
patients with IBS, has been demonstrated by other re-
search [15-18]. Notably, in IBS patients who undergo
cholecystectomy, the presence of acute cholecystitis con-
firmed by tissue analysis of the resected gallbladder does
not appear to be greater than that in patients without
IBS [18]. These results suggest that gallbladder surgery
may be used as a part of symptom evaluation in some
patients. Certainly, there is no evidence that tegaserod
affects gall bladder contraction or emptying [19].
Further, there may have been misclassification of IBS,
particularly among the comparator cohort of this study,
since the diagnosis codes for IBS have been found to be
associated with substantial clinical heterogeneity [20,21].
If gallbladder surgery had been part of the symptom
evaluation the IBS patients included in this study, there
may have been distant past gallbladder surgery among
some of the patients included, and these patients would
be at lower risk of gallbladder surgery. Without access
to a data source with extensive patient history to ascer-
tain these remote gallbladder surgeries, the incidence
estimates in this study may be underestimated as a re-
sult. If this underestimate of incidence were substantial,
tegaserod effects on gallbladder surgery could be
obscured (biased toward a null finding), but this effect
would be considerably less pronounced for the outcome
of general abdominal surgeries so the consistency of
study results for these two outcomes is reassuring.
The incidence rates observed in the current study
(323/10,000 person-years for gallbladder surgery and
854/10,000 person-years for abdominal and pelvic sur-
gery among tegaserod initiators) suggest that those
patients for whom tegaserod is prescribed are at elevated
risk of later undergoing gallbladder surgery (although
not abdominal or pelvic surgery) relative to those with
IBS in earlier studies and at considerably increased risk
of both categories of surgery when compared to the gen-
eral population. The variation in reported incidence
rates of abdominal surgery across studies underscores
the importance of using an internal comparison group
rather than an external or historical comparison group.
Our matched comparison cohort was identified through
propensity scores derived from health insurance claims
so that it was not only contemporaneous with the tega-
serod initiator cohort, but also was similar to it with re-
spect to many baseline characteristics including
demographics, diagnoses, procedures, drugs, and health-
care utilization. The similarity of the matched cohorts
with respect to so many variables serves to address nu-
merous potential confounding scenarios as alternate
explanations for our findings. Any suggestion that the
observed lack of increase in abdominal or pelvic surgery
with tegaserod use is the result of a baseline difference
between the compared groups would be predicated on
the existence of a characteristic that predicts abdominal
surgery and is sufficiently different between compared
groups as to have obscured a real effect of tegaserod.
Such a characteristic would have to be largely independ-
ent of the characteristics that were closely balanced
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this effect, and the numerous variables that were part of
the propensity score make this unlikely. Accordingly, the
internal comparison of outcomes within this study
should not be confounded by baseline differences among
tegaserod users and comparators.
We identified study outcomes (abdominal and pelvic
surgeries or gallbladder surgeries) during follow-up of
the cohorts on the basis of claims for abdominal surgical
services, a case screening process designed to have high
sensitivity, since essentially all abdominal surgical proce-
dures would be claimed through health insurance. We
obtained medical records for most of the surgeries iden-
tified, and our surgery verification process had the effect
of ensuring that all surgeries in this analysis met clinical
criteria. This confirmation addresses the inherent limita-
tion of insurance claims databases where the administra-
tive purpose of a claim may result in a lack of
correspondence between the claim and the underlying
clinical condition. This case conformation also gives our
study outcomes essentially complete specificity while
retaining the high sensitivity of our original insurance
claims screening.
The percentage of study outcomes that were con-
firmed upon review of the medical records reflects on
the comprehensiveness of the initial screen where a wide
range of surgical procedure claims brought to our atten-
tion many potential study outcomes including relatively
minor surgeries and even non-surgical procedures that
ultimately did not meet our study outcome definition
when we reviewed the medical records. This compre-
hensive initial screen coupled with medical record re-
view provides assurance of the completeness and
accuracy of outcome ascertainment. The subset of po-
tential study outcomes for which we could not obtain
medical records was equally distributed among tega-
serod and comparator cohorts and reflected an under-
lying mechanism that was largely administrative in
nature (provider or facility refusal, archived or missing
records, practice or facility closure). Accordingly, the
estimated association between tegaserod use and study
outcomes is not biased by differential outcome ascer-
tainment, since the absolute incidence of study outcome
is underestimated by a similar magnitude in the tega-
serod and comparator cohorts.
Conclusions
The results of the current study provide evidence that
tegaserod does not increase the risk of either abdominal
surgery or gallbladder surgery (including cholecystec-
tomy), a finding that was consistently observed under
different definitions of exposure, and did not appear to
be confounded by any baseline differences of the tega-
serod initiators.
Appendix A: abdominal or pelvic surgery
definition
A procedure performed under general endotracheal
anesthesia by a surgeon (including a gynecologist or ur-
ologist) that involves entrance into the peritoneal cavity
via incision with a scalpel, or via perforation with a
laparoscopy trocar.
Examples include:
a)Exploration of the peritoneal cavity
b)Partial or complete excision, repair, or transplantation
of an abdominopelvic organ or body part
c)Repair of inguinal, femoral or incisional hernia
d)Placement or removal of a tube, catheter, or medical
device
e)Lysis, vaporization, or cauterization of tissue
f) Evacuation of tissue, fluid, or foreign material
Or,
A procedure performed under regional anesthesia
(e.g., peripheral nerve, plexus, or neuraxial blockade) or
general anesthesia, involving an incision into the vaginal
or rectal wall of at least 1 cm in length, or penetration
into the ischiorectal fossa.
Examples include:
a) Hemorrhoidectomy (i.e., not rubber band ligation)
b)Repair procedures for pelvic organ prolapse,
including stress urinary incontinence
c)Incision and drainage of perirectal abscess
This definition excludes endoscopic procedures by
gastroenterologists, or other specialists, and procedures
involving the insertion or removal of tubes/catheters, or
aspiration of fluid/tissue, by radiologists, via percutan-
eous penetration of the peritoneal cavity with a large
bore needle.
Examples of Abdominal or Pelvic Surgical Procedures
By Organ
Distal esophagus
 Nissen fundoplication
 Total and distal esophagectomy
 Jejunal or colonic interposition for esophageal
replacement
Stomach
 Partial or total gastrectomy
 Gastrostomy
 Gastrodudenostomy
 Pyloroplasty
 Vagotomy
 Gastric stapling or bypass for obesity
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 Ileostomy
 Jejunostomy tube placement
 Partial resections
 Intestinal bypass procedures
Appendix
 Appendectomy
Colon
 Colostomy
 Partial colectomy
 Total abdominoperineal resection
Rectum or Anus
 Total abdominoperineal resection
 Anterior resection of rectum
 Repair of rectal prolapse, involving an abdominal
approach
Pancreas
 Pancreaticojejunostomy
 Partial or subtotal and total pancreatectomy
 Repair for trauma
 Cystogastrostomy and cystojejunostomy for
pancreatic pseudocyst
Abdominal Wall (Hernia)
 Abdominal incisional hernias
 Inguinal hernias
Other Procedures Involving the Abdomen or Pelvis
 Splenectomy, partial or total
 Ventriculo-caval shunts
 Vascular bypass or repair procedures requiring a
transabdominal approach (abdominal aorta, iliac
arteries, etc.)
 Adrenalectomy
 Retroperitoneal, pelvic, and mesenteric lymph node
dissections
Gallbladder or Bile Ducts
 Wedge biopsy
 Lobectomy or complete hepatectomy (i.e., for
transplantation)
 Repair of liver injuries from trauma
 Drainage of abscesses, cysts, etc.
 Cholecystostomy
 Cholecystectomy
 Choledochojejunostomy
 Sphincteroplasty
 Portacaval shunts
Urinary Tract
 Partial and total nephrectomy
 Cystostomy
 Partial or total cystectomy
 Urinary diversion procedures
Female Genital
 Simple abdominal or vaginal hysterectomy with or
without salpingo-oophorectomy
 Cesarean section
 Tubal sterilization procedure
 Cystocele repair with abdominal approach (e.g.,
Marshall Marchetti procedure, and not anterior or
posterior colporrhaphy)
Male Genital
 Radical prostatectomy
 Radical orchiectomy
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